Bronchodilator Effect of Oral Doxofylline and Procaterol in Chronic Obstructive Pulmonary Disease - Trial NCT06346691
Access comprehensive clinical trial information for NCT06346691 through Pure Global AI's free database. This Phase 4 trial is sponsored by Thammasat University and is currently Not yet recruiting. The study focuses on COPD. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Thammasat University
Timeline & Enrollment
Phase 4
Apr 16, 2024
Dec 31, 2024
Primary Outcome
Forced expiratory volume in 1 second (FEV1),Forced vital capacity (FVC),Forced expiratory flow at 25-75% of FVC (FEF25-75)
Summary
The goal of this clinical trial is to determine if doxofylline and procaterol are effective
 in treating patients with stable chronic obstructive pulmonary disease (COPD). It will also
 assess the safety of both drugs.
 
 The main questions it aims to answer are:
 
 - Does doxofylline demonstrate a comparable bronchodilator effect to procaterol in COPD
 participants?
 
 - What medical problems do participants experience when taking doxofylline and
 procaterol?
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06346691
Non-Device Trial